How the DMD Hub helps Industry

The DMD Hub works collaboratively with industry partners, to act as a one-stop-shop, providing advice and support as they set-up and run DMD clinical trials. 

We have a flexible approach, evolving and developing additional tools as required, and to provide tailoured support as detailed below:

If you would like any more information about these areas, or about other aspects around setting up DMD trials, please contact DMD Hub Manager, Emma Heslop. 

Collaborators 

The DMD Hub is always actively collaborating with industry partners interested in running clinical trials in the UK. We have also worked closely with academic principal investigators (PIs) to develop academic-led clinical trials. 

We are currently speaking with:

• Antisense Therpeutics
• Fibrogen
• NS Pharma
• Dyne Therapeutics
• Vertex Pharmaceuticals
• Solid Biosciences
• Audentes Therapeutics
• Regenxbio

Below you can find the companies we have supported since 2016, and who we are also working with currently:

	Pfizer Inc	DMD C3391003 (Phase 3) Domagrozumab (Phase 2)
	Reveragen	Vamorolone / VBP15 (Phase 2a/2b) Vamorolone (Phase 2 Extension)
	Duchenne UK / Academic / EU collaboration	Tamoxifen (Phase 2)
	Wave Life Sciences	Next Generation AON Exon Skipping (Phase 1) DYSTANCE 51 (Phase 2)
	Catabasis Pharmaceuticals	PolarisDMD (Phase 3) GalaxyDMD (OLE)
	Santhera Pharmaceuticals	SIDEROS (Phase 3) SIDEROS (OLE)
	Italfarmaco	Givinostat (EPIDYS) (Phase 3) Givinostat (OLE)
	Sarepta Therapeutics	MOMENTUM (Phase 2) Essence (Phase 3) Casimersen/Golodirsen (OLE) Sarepta 53 (Phase 1/2)
	PTC Therapeutics	Ataluren (Phase 3) Ataluren (OLE) Stride Patient Registry
	Roche	RO7239361 (Phase 2/3)
	Summit	Ezutromid (Phase 2)
	Academic Collaboration	Testosterone for DMD (Observational) FOR-DMD (Observational)